Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report

🕔4/27/2021 8:34:50 AM 793

Anatara Lifesciences (ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company's Appendix 4C cash flow report.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Ethics Approve Adult Psychological Functioning Trial start

🕔4/20/2021 8:27:47 AM 1075

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial on the effects of 3FDC dietary supplementation on psychological functioning in an adult population.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Announces Australian Patent Grant for Detach

🕔4/16/2021 9:15:44 AM 1293

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Market Update

🕔4/7/2021 10:34:56 AM 1468

Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Completion of Unmarketable Parcel Share Buy-Back

🕔2/10/2021 8:51:29 AM 1762

On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives Ethics Approval to Start IBS Trial

🕔2/8/2021 9:42:00 AM 1433

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) R&D Tax Incentive Received

🕔2/3/2021 9:33:37 AM 1391

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful Poultry Trial

🕔2/1/2021 8:52:29 AM 1411

Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Cash Report

🕔1/28/2021 10:13:28 AM 1350

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Human Health Update

🕔12/8/2020 8:57:08 AM 2562

Anatara Lifesciences (ASX:ANR) is pleased to advise that it is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon-targeted formulation (3FDC).

Read Full Article
###

67,596 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 178) (Last 30 Days: 2279) (Since Published: 67596) 

Company Data

    Headquarters
  • Level 3, 62 Lygon Street
    Carlton South, VIC, 3053
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports